Search
Skip to Search Results- 6Immunotherapy
- 4Vaccinia virus
- 3Oncolytic virus
- 2Ribonucleotide reductase
- 1Bladder cancer
- 1Breast cancer
- 1Gammon, Donald Brad
- 1Gupta, Nancy
- 1Molavi, Ommoleila
- 1O'Shea, Daire T
- 1Potts, Kyle G
- 1Storozynsky, Quinn
-
Spring 2021
Vaccinia virus (VACV) has shown promise as an oncolytic agent for treating a variety of tumour types, with preliminary results suggesting that this strategy holds promise for treating breast cancer. Our lab has previously modified VACV by deleting virally-encoded enzymes responsible for dNTP...
-
Investigating Radiation in Combination with Oncolytic Vaccinia Virus to Improve the Treatment of Glioblastoma
DownloadFall 2023
Glioblastoma (GBM) is a malignant and immune-suppressed brain cancer that remains incurable despite the current standard of care. Radiotherapy is a mainstay of GBM treatment, however invasive cancer cells outside the irradiated field and radioresistance preclude complete eradication of GBM cells....
-
Delivery of STAT3 inhibitor cucurbitacins to tumor by polymeric nano-carriers : Implications in cancer chemo- and immunotherapy
DownloadFall 2009
Signal Transducer and Activator of Transcription 3 (STAT3), a common oncogenic mediator, is constitutively activated in many types of human cancers and plays a critical role in tumor growth and cancer immune evasion. The focus of this dissertation is the delivery of STAT3 inhibitor cucurbitacins...
-
Spring 2017
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), continues to be a leading infectious cause of death worldwide with approximately 10 million new cases and 2 million deaths attributed annually. There has been resurgence in active TB infections since 1980s and the World Health...
-
Novel Agents Inhibiting Hepatitis C Virus; Application to Prevention of Re-infection after Liver Transplantation
DownloadFall 2013
Recurrent Hepatitis C virus infection drives inferior outcomes experienced by patients undergoing liver transplantation due to HCV-associated liver disease. Existing therapies exhibit increased toxicity, poor efficacy, and profound patient intolerability in the immediate transplantation period....
-
Deletion of F4L (ribonucleotide reductase) in Vaccinia Virus Produces a Selective Oncolytic Virus and Promotes Anti-tumor Immunity with Superior Safety in Bladder Cancer
DownloadFall 2017
Overall recurrence of non-muscle-invasive bladder cancer (NMIBC) can be as high as 80% within 5 years of initial treatment. High-grade NMIBC has the greatest risk of recurrence and treatment for these patients includes surgery followed by intravesical therapy with the immunotherapeutic agent...
-
Vaccinia virus DNA polymerase and ribonucleotide reductase: their role in replication, recombination and drug resistance
DownloadSpring 2010
Despite the eradication of smallpox, poxviruses continue to cause human disease around the world. At the core of poxvirus replication is the efficient and accurate synthesis and repair of the viral genome. The viral DNA polymerase is critical for these processes. Acyclic nucleoside phosphonate...